check_circleStudy Completed

Prevention of venous thromboembolism after MOS

BAY59-7939, Interaction Study with Fluconazole

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 45 Years
  • -

  • -

Trial summary

Enrollment Goal
13
Trial Dates
June 2010 - June 2010
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer HealthCareWuppertal, 42096, Germany

Trial design

Randomized, open label, 2-fold cross-over study to investigate the influence of multiple doses of 400 mg fluconazole on safety, tolerability, and pharmacokinetics of a single oral dose of 20 mg rivaroxaban in healthy male subjects
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A